Replies to post #42523 on Humanigen Inc (HGENQ)

[ZenNavigator54]

The Lenzi molecule was originally clinically trialed for a rare blood cancer and problem is it was no effective and doesn't cure blood cancer? less than. 0001% of the pop have this type of rare blood disorder like the drug disorder Count Dracula has. Viral inflammation is much more higher with corvid infection but was not part of the original FDA application approval or clinical trials The use of LENZI was the side effect or reducing inflammation by viral infections. it's anti-viral drug not anti-cancer drug.
Either the company use new trials to show the molecule is effective in reducing inflammation for viral infection or not enough data to prove it is effective in reducing viral infection deaths.
Either way if the drug does work and the public is not given the opportunity to use the drug, than that would be another issue of the FDA. but the lenzi drug like many drugs need 5-10 years of clinical trials to prove it works or has no severe side effects to solve a particular health issue. obviously for blood cancer, lenizi application may not be effective as other drugs already in the market for treating blood cancers due to the fact there is not a lot of people with these rare blood disorders and not much market for the drug

[cowtown jay]

Chances are that I misinterpreted the meaning of the 'Covid Mono vaccine,' and that mono, in this sense, means monovalent.

"On May 10, 2024, Novavax, Inc. (the “Company”) entered into a collaboration and license agreement (the “Collaboration and License Agreement”) with Sanofi Pasteur Inc. (“Sanofi”) pursuant to which Sanofi received:

i) A co-exclusive license to commercialize with the Company all of the Company’s current standalone COVID-19 vaccine products, including the Company’s NuvaxovidTM prototype COVID-19 vaccine and NuvaxovidTM updated COVID-19 vaccine, and updated versions that address seasonal variants throughout the world (“COVID Mono Products”)..."

https://www.sec.gov/ix?doc=/Archives/edgar/data/1000694/000110465924060444/tm2414089d1_8k.htm

But the term "co-exclusive license" poses the question, who is the licensor? I think Taran will be revealed as the licensor.

I received the proxy material this morning from my broker, even though it is assumed that I would vote against the Combined Plan and the Disclosure Statement. The hearing has been set for June 13th, 2024.

The Hearing will not interfere with Taran's licensing the use of the patented vaccine enhancement, using lenz, to Novavax and Sanofi.

Nor will the Hearing derail progress in the various on-going clinical trials for CMML, aGvHD, and Mayo Clinic's CAR-T. In fact, success in these trials will cause a sharp increase in price for shares of Humanigen, (or the merged entity with Taran), and will result in the company's recall of their loaned shares.